What is Qcdx?
Qcdx operates at the intersection of medical device engineering and oncology, specializing in the detection and isolation of circulating tumor cells (CTCs). The company's core technology facilitates enrichment-free profiling, allowing for real-time cancer intelligence derived from minimally invasive blood samples. This approach provides oncologists and pharmaceutical researchers with high-fidelity data regarding tumor behavior, treatment efficacy, and potential toxicity.
By moving beyond traditional biopsy methods, Qcdx offers a streamlined, patient-centric alternative that supports longitudinal monitoring of cancer progression. Their solutions are designed to integrate seamlessly into existing clinical workflows, providing essential insights that drive personalized treatment strategies and support the rigorous demands of modern drug discovery pipelines.
How much funding has Qcdx raised?
Qcdx has raised a total of $7M across 2 funding rounds:
Debt
$14K
Other Financing Round
$7M
Debt (2021): $14K with participation from PPP
Other Financing Round (2025): $7M, investors not publicly disclosed
Key Investors in Qcdx
PPP
Public-Private Partnership
Undisclosed Investor
An undisclosed investor participating in the funding round, typically focused on long-term value creation in the medical technology sector.
Undisclosed Investor
An undisclosed investor participating in the funding round, specializing in early-stage and growth-stage biotech and life sciences innovation.
What's next for Qcdx?
With the recent infusion of capital, Qcdx is poised to transition into a more aggressive phase of commercialization and clinical validation. The strategic roadmap likely includes expanding the reach of its CTC profiling technology into broader oncology markets and deepening partnerships with pharmaceutical entities engaged in late-stage drug trials.
Future growth will be defined by the company's ability to translate its technical breakthroughs into standardized clinical protocols. As the demand for precision diagnostics continues to rise, Qcdx is strategically positioned to capitalize on the shift toward data-driven cancer care, potentially setting new benchmarks for diagnostic accuracy and patient monitoring in the global healthcare sector.
